SignaBlok is a biopharmaceutical company that aims to improve lives by understanding and harnessing the power of nature. With a focus on developing novel mechanism-based targeted therapeutics and delivery nanosystems, SignaBlok utilizes revolutionary science and technologies. The company's founder, Dr.

Alexander B. Sigalov, is a renowned scientist with over 35 years of academic and industry experience in biophysics, biochemistry, immunology, and cell biology. His groundbreaking discovery of the homooligomerization of intrinsically disordered proteins led to the development of the Signaling Chain HOmoOLigomerization (SCHOOL) model, which revolutionizes our understanding of receptor signaling.

SignaBlok's innovative approach involves disrupting the functional coupling between recognition and signaling in cell receptor machinery. This breakthrough allows for the modulation of receptor signaling, offering effective ways to prevent and treat various serious diseases. The company's modulatory SCHOOL peptides, mimicking natural structures, can be designed for almost any receptor and possess unique drug-like properties.

Additionally, SignaBlok develops integrated nanosystems for targeted drug delivery to sites of inflammation, utilizing nature-inspired multifunctional nanoparticles. These nanosystems have applications in cancer, atherosclerosis, sepsis, rheumatoid arthritis, and other inflammation-associated diseases. By capitalizing on billions of years of virus evolution, SignaBlok is at the forefront of disruptive therapies and is dedicated to revolutionizing drug discovery science